Rippling muscle disease with myasthenia gravis

Rippling muscle disease with myasthenia gravis (Orphanet code 206575) is an extremely rare neuromuscular condition that combines two distinct clinical features: rippling muscle disease (RMD) and myasthenia gravis (MG). Rippling muscle disease is characterized by mechanically triggered, wave-like contractions (rippling) of skeletal muscles, muscle mounding (localized swelling of muscle when percussed or pressed), and muscle stiffness. These rippling movements are electrically silent on electromyography, distinguishing them from other forms of muscle hyperexcitability. Myasthenia gravis adds fatigable weakness of voluntary muscles, particularly affecting ocular, bulbar, and limb muscles, due to autoimmune disruption of neuromuscular junction transmission. The combination of these two conditions suggests an autoimmune mechanism, as many cases of rippling muscle disease associated with myasthenia gravis involve autoantibodies against muscle proteins, particularly caveolin-3 or other muscle membrane components. Patients may experience exercise intolerance, muscle cramps, progressive weakness, ptosis, diplopia, and difficulty swallowing. The musculoskeletal and neuromuscular junction systems are primarily affected. Treatment is directed at managing both components of the disease. Myasthenia gravis is typically treated with acetylcholinesterase inhibitors (such as pyridostigmine), immunosuppressive therapies, and in some cases thymectomy. The rippling muscle component may respond to immunosuppressive treatment if autoimmune in origin. Given the rarity of this combined presentation, management is largely guided by expert opinion and individual clinical response rather than large-scale clinical trials.

Common questions about Rippling muscle disease with myasthenia gravis